Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (402)	2/2/2005 10:16:34 AM
From: Icebrg	Respond to of 946

>>Do you mean investigators with long experience in paclitaxel type treatment?>> No, I was mainly thinking of sites having recruited more than a handful of patients in the trial. Such sides should have a better idea about the differences. At one conference call Dr. Bianco mentioned a (East European) site with 23 participants. That almost by itself represents a mini-trial. By looking to sites with a larger number of participating patients, they avoid problems arising from for example different standards of care, which no doubt exist when sites in so many different countries are involved. Erik